Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emily Hanigan

Physician Assistant Omaha, NE Physician Assistant

NPI 1932676889 CMS profile 11094756

7205 W Center Rd Ste 200, Omaha, NE 68124

Open in the dashboard

General payments

$2,784

145 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Hanigan of Omaha, NE is reported in the CMS Open Payments database as having received $2,784 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $397 19
2024 General $557 30
2023 General $759 38
2022 General $423 28
2021 General $648 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Hanigan
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Emily Hanigan were reported at $397. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Emily Hanigan Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $648 $132 $37–$438 $132
2022 $423 $155 $48–$522 $149
2023 $759 $167 $52–$557 $160
2024 $557 $178 $55–$600 $164
2025 $397 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sumitomo Pharma America, Inc. $394 18 payments
  2. AbbVie, Inc. $393 24 payments
  3. Astellas Pharma US Inc $307 10 payments
  4. Novo Nordisk Inc $205 7 payments
  5. Daiichi Sankyo Inc. $174 11 payments
  6. Organon LLC $130 8 payments
  7. GlaxoSmithKline, LLC. $121 1 payment
  8. Myovant Sciences Inc. $105 7 payments
  9. Biogen, Inc. $96 6 payments
  10. Pfizer Inc. $94 7 payments
  11. Other $764 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,604 143 payments
  2. Education $180 2 payments
Products named General payments · program years 2021–2025
  1. MYFEMBREE Hormone Therapy $413 21 payments
  2. INJECTAFER $174 11 payments
  3. LILETTA $153 8 payments
  4. LO LOESTRIN FE $149 10 payments
  5. Wegovy $138 2 payments
  6. SHINGRIX $121 1 payment
  7. Veozah $100 6 payments
  8. MYFEMBREE Genitourinary (Sexual Health);Womens Health $94 7 payments
  9. ORIAHNN $89 6 payments
  10. ORILISSA $89 6 payments
  11. Other $1,518 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record